Cargando…
The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods of scoring: identification of consistencies and key differences
Autores principales: | Bergemann, Rito, Ackermann, Elizabeth, Monia, Brett, Shenker, Andrew, Dyck, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642070/ http://dx.doi.org/10.1186/1750-1172-10-S1-O22 |
Ejemplares similares
-
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020) -
Managing NFS and NIS /
por: Stern, Hal
Publicado: (1992) -
Managing NFS and NIS
por: Eisler, Mike, et al.
Publicado: (2001) -
A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
por: Millns, Helen, et al.
Publicado: (2015) -
Non-Enzymatic Glucose Detection Based on NiS Nanoclusters@NiS Nanosphere in Human Serum and Urine
por: Arivazhagan, Mani, et al.
Publicado: (2021)